Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Pharmaceutical company regains Nasdaq compliance
February 27th, 2006
Savient Pharmaceuticals, Inc. (SVNTE) announced that it has received written notification from the Nasdaq Listing Qualifications Panel of its determination of the company's compliance with the requirements for continued listing on The Nasdaq National Market. As a result of Savient's compliance, the company expects that its trading symbol will be restored to SVNT. Based in East Brunswick, New Jersey, Savient Pharmaceuticals, Inc., is an emerging specialty pharmaceuticals company. The company's lead product development candidate, Puricase, for the treatment of refractory gout has reported positive phase 1 and 2 clinical data. The...
Source: Pharma Business Week (2006-02-27)
|
